KR101821343B1 - 암 진단 및 영상화 - Google Patents

암 진단 및 영상화 Download PDF

Info

Publication number
KR101821343B1
KR101821343B1 KR1020127022975A KR20127022975A KR101821343B1 KR 101821343 B1 KR101821343 B1 KR 101821343B1 KR 1020127022975 A KR1020127022975 A KR 1020127022975A KR 20127022975 A KR20127022975 A KR 20127022975A KR 101821343 B1 KR101821343 B1 KR 101821343B1
Authority
KR
South Korea
Prior art keywords
imaging
mammal
calcium channel
type calcium
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020127022975A
Other languages
English (en)
Korean (ko)
Other versions
KR20130014506A (ko
Inventor
로이드 에스. 그레이
Original Assignee
타우 쎄라퓨틱스 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 타우 쎄라퓨틱스 엘엘씨 filed Critical 타우 쎄라퓨틱스 엘엘씨
Publication of KR20130014506A publication Critical patent/KR20130014506A/ko
Application granted granted Critical
Publication of KR101821343B1 publication Critical patent/KR101821343B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H30/00—ICT specially adapted for the handling or processing of medical images
    • G16H30/20—ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Primary Health Care (AREA)
  • Medical Informatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020127022975A 2010-03-01 2011-02-28 암 진단 및 영상화 Expired - Fee Related KR101821343B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30903010P 2010-03-01 2010-03-01
US61/309,030 2010-03-01
PCT/US2011/026416 WO2011109262A2 (en) 2010-03-01 2011-02-28 Cancer diagnosis and imaging

Publications (2)

Publication Number Publication Date
KR20130014506A KR20130014506A (ko) 2013-02-07
KR101821343B1 true KR101821343B1 (ko) 2018-01-23

Family

ID=44542787

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127022975A Expired - Fee Related KR101821343B1 (ko) 2010-03-01 2011-02-28 암 진단 및 영상화

Country Status (13)

Country Link
US (1) US9427429B2 (https=)
EP (1) EP2542155B1 (https=)
JP (1) JP6017964B2 (https=)
KR (1) KR101821343B1 (https=)
CN (1) CN102781316B (https=)
AU (1) AU2011223883B2 (https=)
CA (1) CA2787673A1 (https=)
ES (1) ES2557407T3 (https=)
IL (1) IL221035A0 (https=)
MX (1) MX360640B (https=)
SG (2) SG183114A1 (https=)
WO (1) WO2011109262A2 (https=)
ZA (1) ZA201205377B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4927735B2 (ja) * 2004-08-20 2012-05-09 ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン Ｔ型カルシウムチャネル阻害剤
AU2011223883B2 (en) 2010-03-01 2015-10-08 Cavion, Inc. Cancer diagnosis and imaging
EP3487516A1 (en) * 2016-07-19 2019-05-29 Bristol-Myers Squibb Company Radioligands for imaging the ido1 enzyme
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
AU2018221722B2 (en) 2017-02-15 2022-02-03 Cavion, Inc. Calcium channel inhibitors
CN113473980A (zh) 2019-03-01 2021-10-01 弗拉梅尔爱尔兰有限公司 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510730A (ja) 2004-08-20 2008-04-10 ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン Ｔ型カルシウムチャネルブロッカーおよび疾患の治療
JP2008510731A (ja) 2004-08-20 2008-04-10 ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン Ｔ型カルシウムチャネル阻害剤
WO2009137378A2 (en) 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1219609A (en) 1968-07-19 1971-01-20 Koninklijke Pharma Fab Nv Diphenylmethoxyethylamino derivatives
US3732247A (en) 1970-08-14 1973-05-08 Robins Co Inc A H 3-di-substituted methylene pyrrolidines wherein the 1-or n-lower-alkyl substituent contains at least two carbon atoms
US4091103A (en) 1976-06-23 1978-05-23 Ciba-Geigy Corporation Quinolyl or isoquinolyl-lower-alkoxy-phenylene-amino derivatives
JPS59161392A (ja) 1983-03-04 1984-09-12 Nippon Shinyaku Co Ltd ジヒドロピリジン誘導体及びその製法
US4906646A (en) 1983-03-31 1990-03-06 Board Of Governors Of Wayne State University Method and composition for the treatment of tumors by administering a platinum coordination compound and a calcium channel blocker compound of the dihydropyridine class
US4885284A (en) 1986-01-22 1989-12-05 Nissan Chemical Industries Ltd. Dihydropyridine-5-phosphonic acid cyclic propylene ester
FR2601366B1 (fr) 1986-07-10 1988-11-25 Andre Buzas Derives de la benzhydryloxyethyl-piperazine, procedes d'obtention et de compositions pharmaceutiques les contenant.
EP0353692B1 (en) 1988-08-02 1995-10-04 Nissan Chemical Industries Ltd. Drug effect-enhancing agent for antitumor drug
JP2850376B2 (ja) 1988-08-02 1999-01-27 日産化学工業株式会社 抗癌剤薬効増強剤
FR2636946B1 (fr) 1988-09-23 1990-11-02 Lipha ((diarylmethoxy)alcoyl)-1 pyrrolidines et piperidines, procedes de preparation et medicaments les contenant
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0467435A3 (en) 1990-07-19 1992-04-01 Akzo N.V. Benzhydryl derivatives having calmodulin inhibitor properties
GB9020051D0 (en) 1990-09-13 1990-10-24 Pfizer Ltd Muscarinic receptor antagonists
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
US6413967B1 (en) 1995-03-30 2002-07-02 The University Of Virginia Patents Foundation Inhibition of novel calcium entry pathway in electrically non-excitable cells acting as an anti-proliferative therapy
WO1997009055A1 (en) 1995-09-08 1997-03-13 Beth Israel Deaconess Medical Center Isolation of microdomains of caveolae and gpi-anchored proteins
DE69631058T2 (de) 1995-09-15 2004-06-03 Neurosearch A/S Piperindinverbindungen als calcium-kanal-blocker
ATE267207T1 (de) 1996-02-14 2004-06-15 Isis Pharmaceuticals Inc Kohlenhydratmodifizierte luckenhafte oligonukleotide
CA2204082A1 (en) 1996-05-03 1997-11-03 Michael William John Urquhart Pharmaceutical compounds
US6191156B1 (en) 1997-04-11 2001-02-20 The Brigham And Women's Hospital, Inc. Compositions and methods for treating bladder dysfunction
US6703374B1 (en) * 1997-10-30 2004-03-09 The United States Of America As Represented By The Department Of Health And Human Services Nucleosides for imaging and treatment applications
CA2312195A1 (en) 1997-12-03 1999-06-10 Merck & Co., Inc. Low-voltage activated calcium channel compositions and methods
EP1036170A1 (en) 1997-12-05 2000-09-20 Loyola University Of Chicago T-type voltage-gated calcium channels and method of using same
US6372719B1 (en) 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
JPH11246417A (ja) 1998-03-04 1999-09-14 Nissan Chem Ind Ltd 糖尿病性腎症治療用医薬組成物
CA2340586A1 (en) 1998-08-26 2000-03-23 South Alabama Medical Science Foundation T-type calcium channel
US6251886B1 (en) 1998-12-07 2001-06-26 Schering Corporation Methods of using temozolomide in the treatment of cancers
JP4932994B2 (ja) 1999-04-07 2012-05-16 ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン 抗癌性カルシウムチャンネル遮断薬
US6946475B1 (en) 1999-04-07 2005-09-20 University Of Virginia Patent Foundation Anticancer calcium channel blockers
US7195783B2 (en) 1999-07-09 2007-03-27 Fx Life Sciences International Gmbh Hypericin and hypericum extract: specific T-type calcium channel blocker, and their use as T-type calcium channel targeted therapeutics
WO2001062740A1 (en) 2000-02-25 2001-08-30 South Alabama Medical Science Foundation Mibefradil analogues and their use
GB0008269D0 (en) 2000-04-05 2000-05-24 Astrazeneca Ab Combination chemotherapy
AU2001278045B2 (en) 2000-07-27 2006-08-03 Pharmacia Corporation Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
ZA200305980B (en) 2001-02-12 2007-01-31 Res Dev Foundation Modified proteins, designer toxins, and methods of making thereof
EP1392361A4 (en) * 2001-05-11 2009-08-05 Univ Texas ANTI-CD26 MONOCLONAL ANTIBODIES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH CD26 EXPRESSIVE CELLS
AU2002328945A1 (en) 2001-07-23 2003-02-24 Epidauros Biotechnologie Ag Methods for improved treatment of cancer with irinotecan based on mrp1
AU2003237616B2 (en) 2002-01-17 2007-07-05 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
AU2003237863A1 (en) 2002-05-20 2003-12-12 Research Development Foundation Aerosol drug inhibition of lung metastases
GB0211578D0 (en) * 2002-05-21 2002-06-26 Univ Belfast Medicaments
DE10227511A1 (de) 2002-06-19 2004-01-08 Max-Delbrück-Centrum für Molekulare Medizin Mittel zur medikamentösen Behandlung von akuten und chronischen Schmerzen
US7985422B2 (en) 2002-08-05 2011-07-26 Torrent Pharmaceuticals Limited Dosage form
AU2003272539A1 (en) * 2002-09-17 2004-04-08 New York University Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors
TW200503733A (en) 2003-03-28 2005-02-01 Nissan Chemical Ind Ltd T-shaped channel blockers
TW200528107A (en) 2003-11-25 2005-09-01 Nissan Chemical Ind Ltd T-type calcium channel inhibitor
JP2008501633A (ja) 2004-02-11 2008-01-24 ユニバーシティ オブ ヴァージニア パテント ファウンデーション 癌の診断及び治療のためのＣａｖ３アイソフォーム及びそのδ２５スプライスバリアントの阻害
AU2011203315B8 (en) 2004-02-11 2012-02-16 University Of Virginia Patent Foundation Inhibiting CAV3 isoforms and the delta25B splice varients for the diagnosis and treatment of cancer
CA2555208A1 (en) 2004-02-18 2005-09-01 Merck & Co., Inc. Nucleic acid molecules encoding novel murine low-voltage activated calcium channel proteins, designated-alpha 1h, encoded proteins and methods of use thereof
US20060003020A1 (en) 2004-03-11 2006-01-05 The Regents Of The University Of Michigan Anti-metastatic ability of mibefradil and gadolinium
TW200538149A (en) 2004-05-20 2005-12-01 Telik Inc Sensitization to another anticancer therapy and/or amelioration of a side effect of another anticancer therapy by treatment with a GST-activated anticancer compound
WO2006003020A1 (en) 2004-07-02 2006-01-12 L'oreal Compositions containing a triazine derivative, an arylalkyl benzoate derivative and a eutectic n-butylphthalimide/isopropylphthalimide mixture; cosmetic uses thereof
US20100222406A1 (en) 2007-09-11 2010-09-02 University Of Virginia Patent Foundation T Type Calcium Channel Blockers and the Treatment of Diseases
US20120264804A1 (en) 2004-08-20 2012-10-18 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
US7851431B2 (en) 2005-07-27 2010-12-14 Prescription Dispensing Laboratories Treatment of actinic keratoses with calcium channel blockers
KR100743255B1 (ko) 2006-05-04 2007-07-27 한국과학기술연구원 Ｔ-형 칼슘 채널에 활성을 지닌 신규1,3-다이옥소아이소인돌 유도체
WO2008018642A2 (en) 2006-08-10 2008-02-14 Oncotherapy Science, Inc. Genes and polypeptides relating to breast cancers
CN101528768A (zh) * 2006-08-10 2009-09-09 肿瘤疗法科学股份有限公司 与乳腺癌相关的基因和多肽
TWI577695B (zh) 2006-12-19 2017-04-11 建南德克公司 用於輔助及先導性輔助療法之血管內皮生長因子（ｖｅｇｆ）-特異性拮抗劑及早期腫瘤之治療
CA2684938A1 (en) 2007-05-02 2008-11-13 Tau Therapeutics Llc Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
WO2008141189A1 (en) 2007-05-09 2008-11-20 Elixir Pharmaceuticals, Inc. Ghrelin modulating compounds and combinations thereof
EP3050566B1 (en) 2007-09-10 2018-11-28 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
JP5029328B2 (ja) 2007-12-05 2012-09-19 マツダ株式会社 自動車の前部車体構造
CN104402998A (zh) 2008-07-08 2015-03-11 昂考梅德药品有限公司 分离的抗体
KR20120030112A (ko) 2009-06-05 2012-03-27 타우 쎄라퓨틱스 엘엘씨 암 또는 전암성 질환을 치료하기 위한 인터레이스 방법
AU2011223883B2 (en) 2010-03-01 2015-10-08 Cavion, Inc. Cancer diagnosis and imaging
SG10201601917XA (en) 2011-09-12 2016-04-28 Tau Therapeutics Llc Antagonists of products of the hs.459642 unigene cluster for the inhibition of proliferation, development or differentiation of stem cells including cancer stem cells

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008510730A (ja) 2004-08-20 2008-04-10 ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン Ｔ型カルシウムチャネルブロッカーおよび疾患の治療
JP2008510731A (ja) 2004-08-20 2008-04-10 ユニバーシテイ・オブ・バージニア・パテント・フアウンデーシヨン Ｔ型カルシウムチャネル阻害剤
WO2009137378A2 (en) 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer

Also Published As

Publication number Publication date
US9427429B2 (en) 2016-08-30
AU2011223883B2 (en) 2015-10-08
SG10201501496TA (en) 2015-04-29
HK1179143A1 (zh) 2013-09-27
ES2557407T3 (es) 2016-01-25
KR20130014506A (ko) 2013-02-07
WO2011109262A2 (en) 2011-09-09
EP2542155A2 (en) 2013-01-09
SG183114A1 (en) 2012-09-27
CN102781316B (zh) 2016-07-06
CN102781316A (zh) 2012-11-14
WO2011109262A3 (en) 2011-11-17
CA2787673A1 (en) 2011-09-09
EP2542155B1 (en) 2015-11-04
JP6017964B2 (ja) 2016-11-02
IL221035A0 (en) 2012-09-24
AU2011223883A1 (en) 2012-09-13
US20120321561A1 (en) 2012-12-20
MX2012010119A (es) 2012-09-12
EP2542155A4 (en) 2013-07-17
MX360640B (es) 2018-11-09
ZA201205377B (en) 2013-09-25
JP2013521287A (ja) 2013-06-10

Similar Documents

Publication Publication Date Title
KR101821343B1 (ko) 암 진단 및 영상화
US6026317A (en) Myocardial perfusion imaging during coronary vasodilation with selective adenosine A2 receptor agonists
Lapi et al. PET imaging of hypoxia
KR20240116780A (ko) 방사성제약 치료 방법 및 용도
JP2026041867A (ja) 心筋画像化において［１８Ｆ］－Ｆ－ＡｒａＧを使用するための方法および材料
EP2795317B1 (en) Composition for use in a method for cancer selection
Wood et al. [64Cu] diacetyl-bis (N4-methyl-thiosemicarbazone)—a radiotracer for tumor hypoxia
Papadimitriou et al. Utility of positron emission tomography for drug development for heart failure
Kim et al. Radiolabeled chitosan hydrogel containing VEGF enhances angiogenesis in a rodent model of acute myocardial infarction
Paganelli et al. Intraoperative avidination for radionuclide therapy: a prospective new development to accelerate radiotherapy in breast cancer
EP4681741A1 (en) Use of positron myocardial fatty acid metabolism imaging agent and positron 18f-fdg myocardial glucose imaging agent in pet combined imaging
TW202432192A (zh) 用於治療神經膠質母細胞瘤之方法
Lu et al. Synthesis and preliminary evaluation of a novel 18F-labeled 2-nitroimidazole derivative for hypoxia imaging
Adams et al. Radioimmunotherapy of human lymphoma in athymic, nude mice as monitored by 31P nuclear magnetic resonance
Bergström Positron emission tomography in tumor diagnosis and treatment follow-up
KR20210012263A (ko) 신규 암 치료 및 진단용 방사성 화합물이 결합된 인간 EphA2 특이적 모노바디 제조법 및 그의 용도
HK1179143B (en) Method for imaging a disease
RU2737996C1 (ru) Способ оценки динамики неоадъювантной системной терапии рака молочной железы с гиперэкспрессией Her2/neu
Wagner Jr 2003 SNM highlights lecture from proof of principle to proof of value
US20260077072A1 (en) Methods and compositions for imaging malignancies in the bone marrow
US8268888B2 (en) Therapy of malignant neoplasias
Dilsizian SPECT and PET techniques
Wadsworth Oxygenation and radiosensitization consequences of solid tumour perfusion
Nienaber PET in cardiology: current status and clinical expectations
Ji et al. Detection of Thromboembolism with 99mTc-labeled F (ab) 2 Fragment of Anti-glycoprotein IIIa Chimeric Monoclonal Antibody in Beagle Canines

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

D13-X000 Search requested

St.27 status event code: A-1-2-D10-D13-srh-X000

D14-X000 Search report completed

St.27 status event code: A-1-2-D10-D14-srh-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20210118

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210118